Basic considerations in chemotherapy of gynecologic cancer.
D000230:Adenocarcinoma / Q000000981:diagnostic imaging; D000477:Alkylating Agents / Q000378:metabolism / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use / Q000633:toxicity; D005260:Female; D005492:Folic Acid / Q000378:metabolism; D005833:Genital Neoplasms, Female / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D007970:Leukopenia / Q000188:drug therapy; D010166:Palliative Care; D011687:Purines / Q000378:metabolism; D011743:Pyrimidines / Q000378:metabolism; D011859:Radiography; D013921:Thrombocytopenia / Q000188:drug therapy; D014594:Uterine Neoplasms / Q000000981:diagnostic imaging
D000477:Alkylating Agents; D000903:Antibiotics, Antineoplastic; D000963:Antimetabolites; D000970:Antineoplastic Agents; D006728:Hormones; D011687:Purines; D011743:Pyrimidines; D005492:Folic Acid